Daniel J. Chai, M.D. is the Founder and Managing Partner of Turret Capital Management, a healthcare venture building and investment firm based in New York. Dr. Chai has over 20 years of experience as an investor and healthcare entrepreneur. Prior to forming Turret Capital in 2016, Daniel was a Portfolio Manager at several leading hedge funds and investment firms including Citadel, UBS and Neuberger Berman. Dr. Chai was an early investor and board member of Nexgen Spine (acquired by Stryker Corporation), a co-founder of Serenikey Therapeutics (now Terran BioSciences), and a board member of TeraImmune Inc. (acquired by Baudax Bio). Daniel graduated as an Angell Scholar from the University of Michigan and received his B.S. degree with Honors. He received his M.D. degree from Columbia University’s College of Physician & Surgeons.

Henry has over 15 years of financial services experience and global VC/PE with transaction experience across Asia and the US. Most recently, he was Vice President of US Operations at Magna Investments, one of South Korea’s leading healthcare VC firms. Henry works closely with American and Korean life sciences firms to in-license/out-license assets and complete crossborder transactions and has a transaction focus in medical and diagnostics devices. Henry holds a B.S. from the University of Michigan with majors in Biopsychology and Cognitive Science.

Gail has over 30 years of experience in the healthcare industry. She was previously the CEO & President of Vermillion Inc., a leading diagnostics company focused on the development and commercialization of novel multi-proteomics tests. There, Gail forged a partnership with Quest Diagnostics and oversaw the commercial launch of the first FDA-cleared blood test to help diagnose ovarian cancer. Prior to her role at Vermillion, she served on the Executive Management team at Laboratory Corporation of America (NASDAQ: LH), one of the world’s leading diagnostic companies. Her current board appointments include Sword Diagnostics, Inc., NxPrenatal, Inc., and Chembio (NASDAQ: CEMI). In August of 2018, she was appointed as the Chief Business Advisor for the Dell Medical School Catalyst/UT Board. Gail earned a B.S. from the University of Florida and completed an executive management program at the Northwestern University Kellogg School of Management.

Anthony Gallo has more than 30 years of experience in the financial services industry. He has an extensive background with financial and operational administration of alternative asset fund structures, fund of funds, managed accounts, and family office accounting and tax. Prior to founding Concept Fund Services, Anthony was the CFO and Managing Member of ConceptOne, LLC which provided risk and performance analytic solutions, middle and back office support, fund administration, outsourced CFO, and regulatory reporting services to investment managers. Before his career in hedge funds, he was the CFO for Abacus and Associates, a Family Office, and started his public accounting career with Richard A. Eisner and Co. Anthony earned a B.A. in Business Administration from Hofstra University.

Frank Borchetta, J.D. – Frank has over 15 years experience in Intellectual Property law. He began his legal career by assisting pharmaceutical and biotech companies in various patent matters, including patent prosecution and litigation. Frank has worked at several high profile law firms including Loeb & Loeb. He was also an attorney at Ascent Biomedical Ventures, where he was responsible for patent portfolio analysis. Frank also has direct experience operating early stage companies as the Chief Executive Officer of Repairogen Corporation, a skincare company developing products based on DNA-repair technology. Frank received his J.D. from Boston University.

Ms. Jambhekar brings over 20 years of experience in the areas of product development, product safety, quality assurance and compliance, clinical operations, supply chain management and both U.S. and international regulatory affairs. Over the course of her career she has managed over 250 NDA/IND/ANDA/PMA/510(k)s. Currently, Ms. Jambhekar serves as the President of PBS Regulatory Consulting Group. Ms. Jambhekar held various roles of increasing responsibility at Paramount BioSciences, Ethicon, a J&J company, Baxter AAC and Bristol-Myers Squibb. Ms. Jambhekar holds her M.Sc. in Organic & Biochemistry and her M.S. in Pharmacy.

Ling has over 20 years of experience in the biotechnology and life sciences industry. She is the founder and principal force behind Radiant Horizons Consulting, LLC, a top-tier consultancy serving the unique demands of the biotech industries and life sciences focused VC funds. Previously, Ling has been a senior biotech analyst at prestigious wall street firms including Blackrock Life Sciences Fund, JP Morgan, and Oppenheimer & Co. She has a BS in Biology from Peking University, an MS in Molecular Pharmacology from Albert Einstein School of Medicine, and an MBA in Finance from Yale University.

Vedik is an investment professional with a multi-disciplinary life sciences and business background. Most recently, he was at GIC, the sovereign wealth fund of Singapore. Vedik covered public equity pharmaceutical companies, and sourced private, early- and growth-stage biotechnology companies for GIC's healthcare investment team. Vedik graduated from the Roy and Diana Vagelos Program in Life Sciences & Management at the University of Pennsylvania, where he earned both a B.A. in Neuroscience, and a B.S. in Economics from The Wharton School with a concentration in Finance.

Shelby has over three years of marketing experience. Upon graduation from college she was Business Manager at Back Home Living, where she was directly responsible for marketing, sales, and staff training. Additionally, she has spent time in China and Thailand and has also conducted social media research on marketing trends in Indonesia and Singapore. Shelby was an intern at Turret Capital where she helped the firm expand its presence in Asia. She received her B.A. from the University of Texas at Austin.